Coverage Crisis: Insurers Restrict Access to Weight Loss Drugs, Sparking Outrage
Table of Contents
With roughly two in five U.S. adults affected by obesity, GLP-1 drugs have emerged as a promising treatment option – but escalating costs are creating a significant barrier to access, as insurance companies increasingly limit coverage.
These medications, including popular options like Wegovy and Mounjaro, currently carry a list price ranging from $936 to $1,349 per month before insurance, rebates, or other discounts are applied. This financial burden has prompted several insurers to curtail coverage for weight loss specifically, while generally maintaining access for patients with diabetes, igniting a fierce debate among medical professionals and patient advocates.
The situation has become so critical that some believe decisive federal intervention is necessary. “Comprehensive coverage, potentially through an executive order from the White House, may be what’s needed to ensure this drug is available to those who need it,” one source familiar with the matter stated.
The trend is already taking shape. As of January 1, Blue Cross Blue Shield of Massachusetts (BCBSMA) will no longer cover GLP-1s for weight loss for employers with fewer than 100 employees. Larger employers – those with over 100 employees – can opt to include the drugs in their benefits packages at an additional cost. This policy applies to both self-insured and fully-insured employer plans.
“We’ve made this decision after careful consideration and to be responsive to customers who’ve expressed to us that they are no longer able to bear the burden of paying for these high-priced medications,” explained Kelsey Pearse, a spokesperson for BCBSMA.
Harvard Pilgrim Health Care, serving Maine, Massachusetts, Rhode Island, and New Hampshire, is implementing a similar policy, ending GLP-1 coverage for weight loss for most commercial plans starting January 1. Larger, fully-insured employers can choose to continue coverage by paying an additional fee. Members of these plans will be required to complete a six-month behavioral modification program before accessing the medication, unless they are already receiving treatment.
According to a spokesperson for Harvard Pilgrim Health Care, the decision is driven by anticipated cost increases stemming from pending FDA approvals for weight loss medications targeting other conditions like cardiovascular disease. “Given the current pipeline of pending future FDA approvals of weight loss medications for alternative indications including cardiovascular conditions and other comorbidities, this action is being taken to ensure affordability of coverage for all our members,” the spokesperson said.
While a precise tally of insurers dropping coverage remains unavailable, other companies announcing similar restrictions include Blue Cross Blue Shield of Michigan, RWJBarnabas Health for its employees, and Ascension for its employees. Medicare currently does not cover GLP-1s for weight loss, and some state Medicaid programs, including North Carolina, are also rolling back coverage. A previous attempt by the Biden administration to expand Medicare and Medicaid coverage was ultimately stalled by the Trump administration.
A recent survey by the Business Group on Health reveals a disparity in coverage based on condition: 73% of self-insured employers cover GLP-1s for obesity, while 99% cover them for diabetes. To manage costs, some employers are raising the body mass index (BMI) threshold required for coverage.
Responding to the trend, a spokesperson for America’s Health Insurance Plans (AHIP) acknowledged the complexity of obesity. “Obesity is a complex, chronic condition that affects millions and requires individualized care,” said Conner Coles, the spokesperson. “While GLP-1s have emerged as a treatment option for some patients, they are not universally appropriate and can present risks or challenges. Health plans continue to assess clinical evidence and work with experts to support coverage policies that prioritize safe, effective, and clinically appropriate care for weight loss.”
The Medical Community’s Concerns
Physicians and advocates are voicing strong opposition to the coverage rollbacks, arguing that restricting access to these medications is a dangerous and short-sighted approach. One obesity medicine physician characterized the decisions as potentially negligent.
“I think it’s the wrong thing to do. I mean, it’s malpractice, if insurance companies could be held to malpractice standards,” stated Dr. Angela Fitch, co-founder and chief medical officer of metabolic health company knownwell, and former president of the Obesity Medicine Association. “If I have a patient with obesity today and I’m seeing them, and I don’t recommend that they go on this type of treatment, I think you could consider it malpractice today, given the data that we have [on how well these drugs work]. Especially if that patient had multiple other issues that they had along with their obesity.”
Dr. Fitch explained that when patients lack insurance coverage, they are often forced to pay out-of-pocket and utilize manufacturer’s direct-to-consumer programs like Novo Nordisk’s NovoCare or Eli Lilly’s LillyDirect, or switch to older medications that may require more frequent visits and carry a higher risk of side effects.
Healthcare advocates share these concerns. Millicent Gorham, CEO of the Alliance for Women’s Health and Prevention and leader of the EveryBODY Covered campaign, highlighted the disproportionate impact on women. “To see insurers roll back coverage of these evidence-based therapies is deeply concerning, as these decisions reinforce the culture of stigmatization for women living with obesity, while also exacerbating health complications associated with the disease,” she said. “We as a society need to break from the misguided belief that obesity is a result of ‘poor lifestyle choices.’ Obesity management medications aren’t ‘vanity drugs,’ they are critical interventions for a serious chronic disease.” Gorham emphasized the broader health benefits of treating obesity, arguing that coverage leads to fewer emergency room visits, surgeries, and instances of disability and absenteeism.
DoseSpot, a prescription management software company, is responding to the uncertainty by providing resources to both patients and providers regarding financial assistance programs. “We’re bringing more power into the patient’s hands, advocating for their ability to see pricing of medication and shop pharmacies that might have the medication at a cheaper price or more convenient, whether it’s mail order or an in-person pharmacy counter experience,” said Josh Weiner, CEO of the company.
Manufacturers Respond, Pricing Remains a Key Issue
The pharmaceutical companies producing these weight loss drugs are also criticizing the insurance coverage decisions.
“We are disappointed by decisions that limit access as it is contrary to actions that many throughout our country are taking to expand coverage for GLP-1s for weight management, recognizing the importance of these medicines for people living with obesity,” said Allison Schneider, director of media relations at Novo Nordisk. “We believe that comprehensive coverage through government and commercial insurance plans is critical to providing more people living with obesity access to affordable healthcare and treatment options.”
Eli Lilly, the manufacturer of Zepbound and Mounjaro, echoed these sentiments, asserting that obesity should receive the same comprehensive coverage as other chronic diseases. “Gaps in insurance coverage disrupt effective care and limit access to safe, evidence-based obesity management medications,” a company spokesperson stated. “Lilly believes access should be guided by clinical evidence, not insurance design.”
However, the manufacturers are not without scrutiny, as they ultimately control the pricing of these medications. Data indicates that Ozempic, for example, can be manufactured for under $5 a month, yet is sold through NovoCare for approximately $500.
The Path Forward: Urgent Action Needed
While past efforts to expand coverage through Medicare and Medicaid may eventually influence employer-sponsored plans, Dr. Fitch believes a more immediate solution is required. She advocates for an executive order mandating obesity treatment as a standard benefit.
“Our health system is not designed to make people well or prevent disease,” she declared. “It’s designed to treat disease after it’s already happened. But we’re in a new era now where we can actually treat the root cause of disease, which is obesity, and prevent all these other diseases, but we need some sort of urgent public health action.”
Dr. Fitch also urged insurers to take the lead. “They could be the hero right now. We need a hero in obesity … because we have revolutionary treatment in our hands as clinicians, and we need the ability to get it out to people.”
